Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 98

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 98
---
 which may limit or prevent investors from selling their Depositary Shares at or above the price paid for the Depositary
Shares, and may otherwise negatively affect the liquidity of our Ordinary Shares and Depositary Shares. The realization of
any of the above risks or any of a broad range of other risks, including those described in these “Risk Factors,” could
have a dramatic and material adverse impact on the market price of our Depositary Shares.

The liquidity of our Depositary Shares may have an adverse effect on share price.

In October 2024, we changed
the ratio of our Ordinary Shares to Depositary Shares, which had the effect of a one-for-25 reverse split of Depositary Shares and reduced
the amount of Depositary Shares publicly traded. There is a risk that there may not be sufficient liquidity in the market to accommodate
significant increases in selling activity or the sale of a large block of our securities. Our Depositary Shares have historically had
limited trading volume, which may also result in volatility.

We may be subject to securities litigation, which is expensive and could divert management attention.

The market price of our Depositary
Shares may be volatile, and in the past, some companies that have experienced volatility in the market price of their stock have been
subject to securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable
judgment. We also may decide to settle lawsuits on unfavorable terms.

Any such negative outcome
could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending
against litigation is costly and time consuming, and could divert our management’s attention and our resources. Furthermore, during
the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings
or developments, which could have a negative effect on the market price of our Depositary Shares.

| 48 |

Shareholder ownership interests in the Company may be diluted as a result of, among other things, future financings and/or additional acquisitions, and may have a material negative effect on the market price of our securities.

We may seek to raise additional
funds from time to time in public or private issuances of equity and such financings may take place in the near future or over the longer
term. Sales of our securities offered through future equity offerings may result in substantial dilution to the interests of our current
shareholders. The sale of a substantial number of securities to investors,